4[Table_MainInfo] 公司研究/汽车与零配件/汽车 证券研究报告 [Table_QuoteInfo] 沪深 300 对比 1M 2M 3M 绝对涨幅（%） 48.0 64.3 68.4 零跑汽车（9863）公司公告点评 2025 年 03 月 14 日 [Table_InvestInfo] 股票数据 | 0[3Ta月b1le3_日S收to盘ck价I（nf港o]币） | 50.10 | | --- | --- | | 52 周股价波动（港币） | 18.64-50.40 | | 总股本/流通股本（百万股） | 1337/1116 | | 总市值/流通市值（百万港币） | 55932/66982 | 相关研究 [《Ta提b前le一_R年e净p利or转tI正nf，o]Q4 毛利率预计 13%》 2025.01.14 《24Q3 销量创历史新高，毛利率环比大幅 改善》2024.11.15 《经营稳健向好，智驾投入加大，全方位与 Stellantis 开展合作》2024.08.16 市场表现 资料来源：海通证券研究所 分析师:刘一鸣 Tel:(021)23154145 Email:lym15114@hai ...

Investment Rating - The investment rating for JD Group is "Buy" with a target price set at 157.2 HKD, maintaining the rating for the next six months [5]. Core Insights - JD Group reported a strong performance in Q4 2024, with revenue reaching 347 billion CNY, a year-on-year increase of 13.4%, surpassing Bloomberg's consensus expectations. The company's Non-GAAP net profit for the same quarter was 11.3 billion CNY, reflecting a 34.5% increase year-on-year [1][4]. - The retail segment of JD Group saw revenue of 307.1 billion CNY in Q4 2024, up 14.7% year-on-year, driven by the optimization of product categories and enhanced service capabilities [2]. - JD Logistics achieved revenue of 52.1 billion CNY in Q4 2024, a 10.4% increase year-on-year, with a notable focus on international expansion and operational efficiency [3]. Summary by Sections Financial Performance - In Q4 2024, JD Group's total revenue was 347 billion CNY, with product revenue at 281 billion CNY and service revenue at 66 billion CNY, marking increases of 14.0% and 10.8% respectively [1]. - For the full year 2024, total revenue reached 1,158.8 billion CNY, a 6.8% increase, while Non-GAAP net profit was 47.8 billion CNY, up 35.8% year-on-year [1]. Retail Segment - JD Retail's revenue in Q4 2024 was 307.1 billion CNY, with a 14.7% year-on-year growth. The operating profit was 10 billion CNY, reflecting a 44.7% increase [2]. - The electronics and home appliances category generated 174.1 billion CNY, a 15.8% increase, benefiting from the "trade-in" policy and service upgrades [2]. Logistics Segment - JD Logistics reported revenue of 52.1 billion CNY in Q4 2024, with a 10.4% year-on-year growth and an operating profit of 1.8 billion CNY, up 37.1% [3]. - The company is expanding its international logistics capabilities, with a focus on enhancing service offerings globally [3]. Shareholder Returns - JD Group has been actively repurchasing shares, completing a buyback of approximately 255 million A shares, representing 8.1% of the shares outstanding as of the end of 2023, with a total expenditure of about 3.6 billion USD [1].

Investment Rating - The report maintains an "Outperform" rating for Genscript Biotech [2][4][6] Core Insights - The deconsolidation of Legend Biotech has led to a significant profit improvement for Genscript, with a profit from discontinued operations of approximately $3 billion, compared to a loss of about $518 million in the same period in 2023 [7][17] - The company expects a positive trend for its continuing business segments in 2025, with projected revenues of $938 million, representing a year-on-year growth of 58% [2][8] - The total equity valuation of Genscript is estimated at $6.296 billion, translating to a target price of HK$22.78 per share [6][17] Summary by Segment Life Sciences Segment - Expected revenue for 2025 is $523 million, with a year-on-year growth rate of 15% and an adjusted operating profit of $104 million [13][14] - The segment's revenue in 2024 was approximately $454.9 million, up by 10.2% year-on-year, with an adjusted gross profit of about $237.7 million [14][17] Biologics Development Services Segment - Projected Fee-for-Service revenue for 2025 is $113 million, up by 19% year-on-year [14][15] - The segment's revenue in 2024 was about $95 million, down by 13.2% year-on-year, but showed signs of recovery in the second half of 2024 [14][17] Industrial Synthetic Biology Products Segment - Expected revenue for 2025 is $67 million, with a year-on-year growth rate of 25% [15][16] - The segment's revenue in 2024 was approximately $53.7 million, up by 24.6% year-on-year [14][17] Legend Biotech - After the deconsolidation, the market capitalization of Legend Biotech was $6.8 billion, with Genscript holding a 47.51% stake valued at approximately $3.231 billion [16][17]

Investment Rating - The report maintains a "Buy" rating for the company [3][7][13] Core Views - The company is expected to achieve a core profit growth of approximately 15.7% year-on-year in 2024, reaching HKD 12.7 billion [2][7] - The target price has been adjusted down to HKD 23.1, reflecting a potential upside of 25.7% from the current price [2][7][13] - The adjustments in profit forecasts for 2025 and 2026 are due to changes in wind and solar project utilization rates and average electricity prices, with profit estimates reduced by 22% and 21% respectively [2][7] Financial Performance - The company’s revenue for 2024 is projected at HKD 104.1 billion, with a slight decrease in operating profit estimates for 2025 and 2026 [6][15] - The expected net profit for 2024 is HKD 12.7 billion, with a net profit margin of 12.2% [6][15] - The company is projected to maintain a dividend payout ratio of 40%, with dividend yields of 5.3% and 5.9% for 2024 and 2025 respectively [7] Capacity and Sales Forecast - The total installed capacity is expected to increase from 68,507 MW in 2024 to 78,507 MW in 2025, with a significant rise in renewable energy capacity [8] - The total electricity sales volume is projected to grow from 207,638 GWh in 2024 to 223,796 GWh in 2025 [8] Valuation - The valuation of the thermal power segment is based on a 0.7x 2025E P/B ratio, while the renewable energy segment is valued at 8.0x 2025E P/E [9] - The total estimated value of the company is HKD 119.6 billion, translating to a per-share value of HKD 23.10 [9]

Investment Rating - The report maintains an "Outperform" rating for Genscript Biotech [2][4][6] Core Insights - The deconsolidation of Legend Biotech has led to a significant profit improvement for Genscript, with a profit from discontinued operations of approximately $3 billion, compared to a loss of about $518 million in the same period last year [7][17] - The company expects a positive trend for its continuing business segments in 2025, with projected revenues of $938 million, representing a year-on-year growth of 58% [2][8] - The total equity valuation of Genscript is estimated at $6.296 billion, translating to a target price of HK$22.78 per share [6][17] Summary by Segment Life Sciences Segment - Expected revenue for 2025 is $523 million, with a year-on-year growth rate of 15% and an adjusted operating profit of $104 million, also growing by 15% [13][14] - The segment's revenue in 2024 was approximately $454.9 million, up by 10.2% year-on-year, with an adjusted gross profit of about $237.7 million [14][17] Biologics Development Services Segment - Projected Fee-for-Service revenue for 2025 is $113 million, up by 19% year-on-year [14][17] - The segment's revenue in 2024 was about $95 million, down by 13.2% year-on-year, but showed signs of recovery in the second half of 2024 [14][17] Industrial Synthetic Biology Products Segment - Expected revenue for 2025 is $67 million, with a year-on-year growth rate of 25% [15][17] - The segment's revenue in 2024 was approximately $53.7 million, up by 24.6% year-on-year [14][17] Legend Biotech - Following the deconsolidation, the market capitalization of Legend Biotech was approximately $6.8 billion, with Genscript holding a 47.51% stake valued at about $3.231 billion [16][17]

Investment Rating - The investment rating for JD Group is "Buy" with a target price set at HKD 157.2, maintaining the rating for the next six months [5]. Core Views - JD Group's Q4 2024 performance exceeded expectations, with revenue reaching CNY 347 billion, a year-on-year increase of 13.4%. The company also reported a significant increase in net profit, with Non-GAAP net profit rising by 34.5% to CNY 11.3 billion [1][4]. - The report highlights the positive impact of government subsidies and the optimization of product categories, which are expected to drive sustainable growth in market share and order volume [2][4]. - JD Logistics is expanding its international presence and enhancing operational efficiency, with revenue growth of 10.4% in Q4 2024, indicating a strong performance in both domestic and international markets [3][4]. Summary by Sections Financial Performance - In Q4 2024, JD Group achieved total revenue of CNY 347 billion, with product revenue at CNY 281 billion and service revenue at CNY 66 billion, reflecting year-on-year growth of 14.0% and 10.8% respectively [1]. - For the full year 2024, total revenue was CNY 1,158.8 billion, a 6.8% increase, with Non-GAAP net profit reaching CNY 47.8 billion, up 35.8% [1]. Retail Segment - JD Retail's revenue for Q4 2024 was CNY 307.1 billion, a 14.7% increase, with operating profit rising by 44.7% to CNY 10 billion [2]. - The electronics and home appliances category saw a revenue increase of 15.8%, driven by the "trade-in" policy and service upgrades [2]. Logistics Segment - JD Logistics reported Q4 2024 revenue of CNY 52.1 billion, a 10.4% increase, with operating profit growing by 37.1% to CNY 1.8 billion [3]. - The company is expanding its logistics capabilities internationally, with a focus on enhancing service offerings for overseas clients [3]. Shareholder Returns - JD Group has completed a share buyback of approximately 255 million A shares, totaling around USD 3.6 billion, and has initiated a new buyback plan of up to USD 5 billion over the next 36 months [1][4].

Investment Rating - The report assigns a "Buy" rating to the company 361 Degrees (1361.HK) with a target price of HKD 5.63, indicating a potential upside of 22.7% from the current price of HKD 4.59 [3][8]. Core Insights - The company is expected to achieve a revenue growth of 20% and a net profit growth of 19% for 2024, aligning with expectations. The end-of-period inventory increased by 56% to HKD 2.1 billion due to early stocking for the Spring Festival [5][6]. - The company plans to expand its "super premium store" concept to 100 locations by the end of 2025, aiming to create a store model akin to "Uniqlo" in the sports industry [7][8]. - The report anticipates a revenue growth of 10-15% for 2025, with a net profit margin projected between 10-12% [8]. Financial Performance Summary - For 2024, the company reported a revenue of HKD 10.07 billion, a year-on-year increase of 20%, and a net profit of HKD 1.15 billion, up 19% [5][9]. - The gross profit margin improved by 0.4 percentage points to 41.5%, while the net profit margin remained stable at 11.4% [5][9]. - The report forecasts revenues of HKD 11.24 billion, HKD 12.41 billion, and HKD 13.66 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.5%, 10.4%, and 10.1% [8][9]. Inventory and Cash Flow Analysis - The company’s inventory turnover days remained stable at 149 days, with a significant increase in inventory due to early stocking [5][9]. - The operating cash flow for 2024 is projected to be HKD 70 million, reflecting the impact of early inventory stocking [5][9].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has received approval for the first global Trop2 ADC lung cancer indication, which aligns with previous expectations [7] - The expansion of indications is favorable for commercialization in China, with the company expected to participate in the 2025 national medical insurance negotiations [7] - The potential of the product is gradually being realized, with ongoing global phase III studies for additional lung cancer indications [7] - 2025 is projected to be a pivotal year for the company's product commercialization, with several products expected to be approved [7] Financial Summary - Revenue projections for the company are as follows: - 2023A: 1,540.5 million RMB - 2024E: 1,746.8 million RMB (growth rate: 13.4%) - 2025E: 1,836.7 million RMB (growth rate: 5.2%) - 2026E: 2,877.2 million RMB (growth rate: 56.7%) [2] - The net profit attributable to the parent company is projected to be negative, with figures as follows: - 2023A: -574.1 million RMB - 2024E: -350.1 million RMB - 2025E: -434.6 million RMB - 2026E: -286.1 million RMB [2] - Earnings per share (EPS) is expected to improve from -2.53 in 2023A to -1.26 in 2026E [2] - The company anticipates significant revenue from the product Lukanosatuzumab, with projected sales of 47 million RMB in 2024, 960 million RMB in 2025, and 1,886 million RMB in 2026 [9] Key Assumptions - The company is expected to receive collaboration payments from Merck, totaling approximately 1.7 billion RMB from 2024 to 2026 [8] - The approval of Lukanosatuzumab in November 2024 is anticipated to generate substantial revenue in the following years [8]

证券研究报告 | 公司点评 gszqdatemark 2025 03 13 年 月 日 中创新航（03931.HK） 海外业务可期，入通改善流动性 2025 年 2 月 24 日，公司发布盈利预喜。根据公司初步评估，2024 年公 司净利润介于 7.86-8.74 亿元，较 2023 年的 4.37 亿元同比增长 80%- 100%。业绩增长的主要驱动因素包括： Q1 出货规模值得期待，关注海外业务。根据高工锂电，中创新航 2025Q1 动储电池出货量预计达 20GWh，同比增幅近 150%。其中，面向出口车型 的出货量预计占中创新航动力板块整体出货量的 30%以上，这可能得益 于：1）2024 年 7 月阳光电源与沙特 ALGIHAZ 成功签约当时全球最大储 能项目，容量高达 7.8GWh，中创新航为该项目供应高性能电芯；2）2024 年 11 月，阳光电源再获欧洲市场 4.4GWh 储能订单，中创新航再次为阳 光电源储能项目配套高性能电芯；3）公司和多家国际车企就新平台项目 达成合作，并助力多个国内车企实现整车出口。 2025 年 3 月 10 日起，中创新航被正式纳入港股通。3 月 9 日中创新航 在港 ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company is leveraging AI technology to create "AI avatars" of top traditional Chinese medicine (TCM) doctors, which is expected to enhance the efficiency and accessibility of TCM services [2][3]. - The integration of AI is anticipated to significantly improve patient experience by providing personalized health management and reducing the workload of doctors [3]. - The company is projected to release several AI avatars of leading experts by July 2025, which could help alleviate the supply bottleneck of quality TCM resources and accelerate revenue growth [2]. Financial Projections - The adjusted net profit forecasts for 2024, 2025, and 2026 are 409 million, 548 million, and 691 million CNY respectively, with corresponding EPS of 1.68, 2.28, and 2.88 CNY [3][4]. - Revenue is expected to grow from 3,042 million CNY in 2024 to 5,006 million CNY in 2026, reflecting a growth rate of 30.95% in 2024 and 27.80% in 2026 [4][9]. - The company is expected to benefit from the aging population and supportive policies in the TCM sector, enhancing its growth potential [3].